Method for preparing microcapsules

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to microcapsulation of drug preparations, vitamins, herbicides, flavouring agents and polysaccharides. The microcapsules are prepared by physical-chemical nonsolvent addition with using benzol as a precipitator.

EFFECT: invention provides simplifying and accelerating the process of preparing the microcapsules, reducing losses in preparing the microcapsules (higher weight yield).

48 ex

 

The invention relates to the field of microencapsulation of drugs, vitamins, herbicides, fragrances and polysaccharides.

Previously known methods for producing microcapsules. Thus, in U.S. Pat. 2092155, IPC AC 047/02, AK 009/16 published 10.10.1997, Russian Federation, proposed a method for microencapsulation of drugs, based on the use of special equipment use of irradiation with ultraviolet rays.

The disadvantages of this method are the duration of the process and the use of ultraviolet radiation, which can influence the formation of microcapsules.

In Pat. 2095055, IPC AC 9/52, AK 9/16, AC 9/10, Russian Federation, published 10.11.1997, method for obtaining solid non-porous microspheres, which comprises melting pharmaceutically inactive substance carrier, the dispersion of a pharmaceutically active substance in the melt in an inert atmosphere, spraying the resulting dispersion in the form of a mist in the freezing chamber under pressure, in an inert atmosphere at a temperature of from -15 to -50°C, and the separation of the obtained microspheres into fractions by size. The suspension is intended for administration by parenteral injection, contains an effective amount of these microspheres, dispersed in a pharmaceutically acceptable liquid vector, when the eat pharmaceutically active substance insoluble microspheres in a specified liquid medium.

Nedostatki of the proposed method: duration of the process, the use of special equipment.

In Pat. 2091071, IPC AC 35/10, Russian Federation, published 27.09.1997, method for obtaining the drug by dispersion in a ball mill to obtain microcapsules.

Disadvantages of the proposed method is the length of the process and application of ball mill, which can lead to the destruction of the microcapsules.

In Pat. 2076765, IPC B01D 9/02, Russian Federation, published 10.04.1997, method for obtaining dispersed particles of soluble compounds in the microcapsules by crystallization from a solution, wherein the solution is dispersed in an inert matrix, cooled and, by changing the temperature, get dispersed particles.

The disadvantage of this method is the difficulty of execution: obtaining microcapsules by dispersion with subsequent change of temperatures, which slows down the process.

In Pat. 2101010, IPC A61K 9/52, A61K 9/50, A61K 9/22, A61K 9/20, A61K 31/19, Russian Federation, published 10.01.1998 proposed chewable form of the drug with taste masking, having the properties of a controlled release drug product that contains microcapsules with a size of 100-800 microns in diameter and consists of pharmaceutical kernel crystalline ibuprofen the polymer coating, including plasticizer, elastic enough to resist chewing. The polymer coating is a copolymer based on methacrylic acid.

The drawbacks of the invention: use of a copolymer based on methacrylic acid, as these polymer coatings can cause cancer; complexity; the duration of the process.

In Pat. 2139046, IPC A61K 9/50, A61K 49/00, A61K 51/00, Russian Federation, published 10.10.1999, method for obtaining microcapsules as follows. Emulsion oil-in-water prepared from organic solution containing dissolved mono-, di-, triglyceride, preferably of tripalmitin or tristearin, and possibly therapeutically active substance, and an aqueous solution containing a surfactant, it is possible to evaporate part of the solvent, add redispersible agent and the mixture is subjected to drying by freezing. Subjected to drying by freezing the mixture is then dispersed in an aqueous medium to separate the particles from organic substances and a hemispherical or spherical microcapsules dried.

Nedostatkami predlozennogo method are the complexity and duration of the process, the use of drying by freezing, which takes time and slows down the process of production of microcapsules.

In Pat. 2159037 IPC A01N 25/28, A01N 25/30, Russian Federation, published 20.11.2000, proposed a method of producing microcapsules by polymerization reaction at the phase boundary, containing solid agrochemical material 0.1 to 55 wt.%, suspended in peremestivsheesya water organic liquid, from 0.01 to 10 wt.% non-ionic dispersant, active on the phase boundary and is not acting as an emulsifier.

Disadvantages of the proposed method: the complexity, duration, using wysokosciowe mixer.

In the article "Razrabotka microencapsulated and gel products and materials for various industries", Russian chemical journal, 2001, .XLV, No. 5-6, s-135, describes a method of producing microcapsules of drugs by the method of gas-phase polymerization, since the authors considered unsuitable method of chemical koatservatsii from aqueous media for microencapsulation of drugs due to the fact that most of them are water-soluble. The process of microencapsulation by the method of gas-phase polymerization using n-xylylene includes the following basic stages: evaporation dimer n-xylylene (170°C), thermal decomposition of it into the pyrolysis furnace (650°C at a residual pressure of 0.5 mm Hg), the transfer of the reaction products in the "cold" chamber of polymerization (20°C, the residual pressure of 0.1 mm RT. Art.), aside the s and polymerization at the surface of the protected object. Luggage polymerization is performed in the form of a rotating drum, the optimal speed for powder coating 30 rpm, the Thickness of the shell is governed by the time of coating. This method is suitable for the encapsulation of any solids (except prone to intense sublimation). The resulting poly-n-xylylene vysokokritichnyh polymer with high orientation and dense packing, provides a conformal coating.

Disadvantages of the proposed method are the complexity and duration of the process, using the method of gas-phase polymerization, which makes the method inapplicable to obtain microcapsules of drugs in polymers protein nature due to the denaturation of proteins at high temperatures.

In the article "Development of micro - and nano drug delivery", Russian chemical journal, 2008, .LII, No. 1, p.48-57, presents a method of obtaining microcapsules included with proteins, which does not significantly reduce their biological activity carried out by the process of interfacial crosslinking of soluble starch or hydroxyethylamine and bovine serum albumin (BSA) using terephthaloyl chloride. The proteinase inhibitor is Aprotinin, either native or protected with the active site, was microcapsular in his introduction to the composition of the aqueous phase. CPF is on form liofilizovannyh particles indicates obtaining microcapsules or particles tank types. Thus prepared microcapsules were not damaged after lyophilization and easily restored its spherical shape after rehydration in a buffered environment. The pH value of the aqueous phase was decisive in obtaining a solid microcapsules with high output.

The disadvantage of the proposed method of producing microcapsules is the complexity of the process that leads to the reduction of the yield of microcapsules.

In Pat. 2173140, IPC A61K 009/50, A61K 009/127, Russian Federation, published 10.09.2001, method for obtaining kremnijorganicheskih microcapsules using a rotary cavitation plants with high shear effort and powerful acoustic phenomena of sound and ultrasound range for dispersion.

The disadvantage of this method is the use of special equipment-rotary-quotational installation, which has ultrasonic action that affects the formation of microcapsules and can cause adverse reactions due to the fact that ultrasound destructive effect on the polymers of protein nature, therefore the proposed method is applicable when working with polymers of synthetic origin.

In Pat. 2359662, IPC A61K 009/56, A61J 003/07, B01J 013/02, A23L 001/00 published 27.06.2009, Russian Federation, proposed a method of producing microcapsules using RA is pilialoha cooling in the spray tower Niro under the following conditions: air temperature at the inlet 10°C, the air temperature at the outlet 28°C, the speed of rotation of the spray drum 10000 rpm/min Microcapsules according to the invention have improved stability and provide adjustable and/or prolonged release of the active ingredient.

Disadvantages of the proposed method are the duration of the process and the use of special equipment, a set of conditions (temperature of inlet air 10°C, the temperature at the outlet 28°C, the speed of rotation of the spray drum 10000 rpm).

In Pat. WO/2009/148058 JP, IPC B01J 13/04 was investigated, A23L 1/00, A61K 35/20, A61K 45/00, A61K 47/08), A61K 47/26, A61K 47/32, A61K 47/34, A61K 47/36, A61K 9/50, B01J 2/04, B01J 2/06 published 10.12.2009, described the process of production of microcapsules, applicable for industrial production, in which a high content of hydrophilic biologically active substances enclosed in the shell. The proposed microcapsules can be used in food, pharmaceutical and other industries. In the production process applied dispersant composition consisting of a hydrophilic biologically active substances and surfactants in solid fat. Temperature not lower than the melting point of the solid fat.

The disadvantages of this method are the complexity and duration of the process of production of microcapsules.

In Pat. WO/2009/153695 IB, IPC B01J 13/16; B01J 13/22; B01J 13/06; B01J 13/20, published the van 23.12.2009, the described method of producing microcapsules, which comprises the following stages: a) dissolving at least one MDI; b) to the mixture obtained in stage a) add the colloidal stabilizer in the form of an aqueous solution of 0.1% to 0.4% of polyvinyl alcohol and from 0.6% to 1% of a cationic copolymer of vinylpyrrolidone; C) to the mixture obtained in paragraph (b) add reagent selected from the group consisting of water-soluble salts of guanidine and guanidine. The invention relates to a method for perfume containing microcapsules with a shell of polyurea that can be used in personal care products. Are used in the invention features a colloidal stabilizers in aqueous solutions containing certain proportions of the polymers.

The disadvantages of this method are the complexity and duration of the process, the use of polyisocyanates, which complicates the process and leads to a low yield of the microcapsules.

In Pat. WO/2009/147973 JP, IPC B01J 13/14; A23L 1/00; A61K 9/50; A61K 47/02; A61K 47/36; A61K 47/44; A23L 1/30 described a method for the production of microcapsules, which includes a step of emulsification: the mixing of fat-soluble substances with an aqueous solution of sodium alginate to form an emulsion in which the emulsified particles having an average particle size of 800 nm or less, and stage of spray: spraying the emulsion in a solution of calcium chloride, stereomicroscopy.

The disadvantages of this method are the complexity and duration of the process, the application of spray.

In Pat. WO/2010/076360 ES, IPC B01J 13/00; AC 9/14; A61K 9/10; A61K 9/12, published 08.07.2010, proposed a new method for obtaining solid micro - and nanoparticles with a homogeneous structure with a particle size less than 10 μm, where the treated solid connections have a natural crystalline, amorphous, polymorphous, and other conditions associated with the reference compound. The method allows to obtain a solid micro - and nanoparticles with a substantially spheroidal morphology.

The disadvantage of the proposed method is the complexity of the process. In Pat. WO/2010/070602 IB, IPC A61K 8/11; A61K 8/84; A61K 8/87; A61Q 5/00; A61Q 13/00; A61Q 19/00; B01J 3/16; C11D 17/00, published 29.07.2010, describes a method for perfume containing microcapsules that can be used in personal care products. The microcapsules comprise a core consisting of at least one aqueous phase dispersed in a continuous oil phase. The microcapsules are formed from the reaction products of at least one of the polyisocyanates and organic compounds containing a Quaternary ammonium group and a primary amine or hydroxyl group. Continuous oil phase comprises (a) a flavoring ingredient or composition and (b) the shell is formed from the reaction products of at least one MDI with one of the organizations the practical connection containing a Quaternary ammonium group and a primary amine or hydroxyl groups of the polyamine or polyol.

The disadvantages of the invention are the complexity and duration of the process, the use of dispersion in the oil phase, the use of polyisocyanates, which complicates the process and leads to a low yield of the microcapsules.

In Pat. WO/2010/025988 EP, IPC B01J 13/04 was investigated, B01J 13/14 published 11.03.2010, the described method and apparatus for producing microparticles of microencapsulate. It should be noted the use of microfluidic in the method and apparatus according to the invention. One of the purposes of the proposed method and device is to provide means for the rapid production of a large volume of monodisperse particles by using the technique of encapsulation with the ability to control the wall thickness of the shell. The advantage of being able to control the wall thickness of the shell is that the rate of release may be in accordance with the needs, for example, by adjusting the resistance to punching shear walls. The method consists of the following steps: a) placing the first liquid composition in microfluidic channels, b) placing a second liquid composition in microfluidic channels thereby to transfer the droplets of the liquid compositions of the first to the second composition of the liquid, the second liquid composition; C) the introduction of the third liquid is a composition in microfluidic channels on the second node is downstream from the first passage; g) coating a second liquid is dispersed in the third liquid composition; (e) polymerization or gelation.

The disadvantages of this method are the complexity, the length of the process, and the use of special installation according to the invention, the method consists of several stages that additionally it is complicated.

In Pat. WO/2010/014011 NL, IPC A61K 9/50; B01J 13/02; A61K 9/50; B01J 3/02, published 4.02.2010 described a method of producing microcapsules with a diameter of from 0.1 μm to 25 μm, comprising: a core particle with a diameter of 90 nm to 23 μm, containing at least 3% active ingredient by weight of the particles; a coating that completely covers the basic particles containing at least 20% by weight of a hydrophobic polymer selected from cellulose esters, cellulose ethers, shellac, gluten, polyacryl, hydrophobic starch derivatives, polyvinyl acetate, polymers or copolymers based acrylic ester acid and/or methacrylic acid ester, and combinations thereof. The active ingredient is not released when introduced into aqueous food products, beverages, food or pharmaceutical composition. Once inside, however, the active ingredient is excreted quickly.

The disadvantages of this method are the complexity, the length of the process, as well as the use of ultrasound and special equipment, as blockmakers copolymers of acrylic or methacrylic acid, which can cause cancer.

In Pat. WO/2010/119041 EP, IPC A23L 1/00, published 21.10.2010, method for obtaining the beads containing the active ingredient encapsulated in the gel matrix whey protein, comprising denatured protein, serum and active components. The invention relates to a method for production of beads that contain components such as probiotic bacteria. The method of receiving beads includes a stage production of beads in accordance with the method of the invention, and the subsequent curing of the beads in the solution of the anionic polysaccharide with a pH of 4.6 and below for at least 10, 30, 60, 90, 120, 180 minutes. Examples of suitable anionic polysaccharides: pectins, alginates, carrageenan. Ideally, whey protein is heat-denaturing, although other methods of denaturation, also applicable, for example, denaturation induced by pressure. In a preferred embodiment, whey protein denaturised at a temperature of from 75°C to 80°C, is properly within from 30 minutes to 50 minutes. Typically, whey protein mixed with thermal denaturation. Accordingly, the concentration of the whey protein is from 5 to 15%, preferably from 7 to 12%, and ideally from 9 to 11% (weight/volume). Typically, the suspension is subject to the filtering process executed by AESA through many filters with a gradual decrease in pore size. Ideally, the fine filter has a submicron pore size, for example, from 0.1 to 0.9 microns. The preferred method of obtaining the beads is a method using vibration encapsulation (Inotech, Switzerland) and machinery manufacturing Nisco Engineering AG. Typically, the nozzles have openings 100 and 600 μm, and ideally about 150 microns.

The disadvantage of this method is the use of special equipment (vibration encapsulation (Inotech, Switzerland)), obtaining microcapsules by denaturation of the protein, the complexity of the allocation obtained by way of microcapsules filtering, using a number of filters that makes the process of selection of microcapsules long.

In Pat. WO/2011/003805 EP, IPC B01J 13/18; B65D 83/14; C08G 18/00, published on 13.01.2011, described a method of producing microcapsules, which are suitable for use in compositions forming sealants, foams, coatings or adhesives.

The disadvantage of the proposed method is the use of centrifugation to separate from the fluid, the length of the process, and the use of this method not in the pharmaceutical industry.

In Pat. 20110223314, IPC B05D 7/00 20060101 B05D 007/00, VS 3/02 20060101 VS 003/02; VS 11/00 20060101 VS 011/00; B05D 1/18 20060101 B05D 001/18; B05D 3/02 20060101 B05D 003/02; B05D 3/06 20060101 B05D 003/06 from 10.03.2011 US described a method of producing microcapsules by the method of suspension polymerization is tomasica to the group of chemical methods with the use of the new device and ultraviolet radiation.

The disadvantage of this method is the complexity and duration of the process, the use of special equipment, obtaining microcapsules by chemical method of suspension polymerization using ultraviolet radiation.

In Pat. WO/2011/150138 US, IPC C11D 3/37; B01J 13/08; C11D 17/00, published on 01.12.2011 described a method of producing microcapsules solid water-soluble agents polymerization method.

The disadvantages of this method are the complexity and duration of the process.

In Pat. WO/2011/127030 US, IPC A61K 8/11; B01J 2/00; B01J 13/06; C11D 3/37; C11D 3/39; C11D 17/00, published on 13.10.2011 proposed several methods for producing microcapsules: interfacial polymerization, thermoanaerobium separation of the phases, spray drying, evaporation of the solvent and other

The disadvantages of the proposed methods is the complexity, duration processes, as well as the use of special equipment (filter (Albet, Dassel, Germany), spray dryer for collecting particles (Spray-M Dryer from ProCepT, Belgium)).

In Pat. WO/2011/104526 GB, IPC B01J 13/00; B01J 13/14; SV 67/00; C09D 11/02, published on 01.09.2011, a method for obtaining a dispersion of encapsulated solid particles in a liquid medium, comprising: a) grinding compositions, including solid, liquid medium and a polyurethane dispersant with an acid number of from 0.55 to 3.5 mmol per gram of dispersant specified composition which I include from 5 to 40 parts of the polyurethane dispersant per 100 parts of the solid, products, by weight; and b) crosslinking the polyurethane dispersant in the presence of solid and liquid media, for encapsulating solid particles which polyurethane dispersant contains less than 10% by weight of the recurring elements of polymeric alcohols.

Nedostatkami of the proposed method are the complexity and duration of the process of production of microcapsules, and that the encapsulated particles of the proposed method are useful as colorants in inks, especially ink jet printing for the pharmaceutical industry this technique is not applicable.

In Pat. WO/2011/056935 US, IPC 3 C11D 17/00; A61K 8/11; B01J 13/02; C11D 3/50, published on 12.05.2011, describes how to obtain microcapsules with a size of 15 microns. As the shell material proposed polymers of the group consisting of polyethylene, polyamides, polystyrene, polyisoprenes, polycarbonates, polyesters, polyacrylates, polyureas, polyurethanes, polyolefins, polysaccharides, epoxy resins, vinyl polymers and mixtures thereof. The proposed polymer membranes are sufficiently impervious core material and materials in the environment in which the encapsulated benefit agent will be used to provide benefits that will be received. The core of the encapsulated agents may include perfume, silicone oils, waxes, hydrocarbons, higher the IRNA acid, essential oils, lipids, cooling the skin fluids, vitamins, sunscreens, antioxidants, glycerin, catalysts, bleach particles, particles of silicon dioxide and other

Disadvantages of the proposed method are the complexity, the length of the process, using as the shells of the microcapsules polymers of synthetic origin, and mixtures thereof.

In Pat. WO/2011/154893 IB, IPC B01J 13/16; C11D 3/50 published on 15.12.2011 described a method of producing microcapsules, comprising the following stages:

a) dissolving the mixture (one aliphatic polyisocyanate and at least one aromatic polyisocyanate containing at least two isocyanate functional groups);

b) adding to the solution obtained in stage a), an aqueous solution of emulsifier or colloidal stabilizers;

C) adding to the mixture obtained in stage b), polyamine for the formation of a suspension of microcapsules. The invention relates to a method for producing a perfume that can be used in personal care products, etc. the Process of the invention uses a combination of aliphatic and aromatic polyisocyanates in certain molar ratios of from 80:20 to 10:90

The disadvantages of this method are the complexity and duration of the process, a multi-stage process of production of microcapsules.

The closest method is way before the its in U.S. Pat. 2134967, IPC A01N 53/00, A01N 25/28 published 27.08.1999, Russian Federation (1999). Water is dispersed solution of a mixture of natural lipids and a PYRETHROID insecticide in the weight ratio of 2-4:1 in an organic solvent, which leads to simplification of the method of microencapsulation.

The disadvantage of this method is the dispersion in the aquatic environment, which makes the proposed method applicable to the production of microcapsules of water-soluble drugs in water-soluble polymers.

The technical objective is the simplification and acceleration of the process of production of microcapsules, the reduction of losses upon receipt of the microcapsules (increase in mass).

The solution of the technical problem is achieved by a method of producing microcapsules, characterized in that the obtaining microcapsules is carried out by physical and chemical deposition method by nerastvorim using benzene as a precipitator, the process of obtaining is performed without special equipment.

A distinctive feature of the proposed method is to obtain microcapsules physico-chemical deposition method by nerastvorim from ispolzovaniem as precipitator.

The result of the proposed method are obtaining microcapsules drugs, herbicides, fragrances, polysaccharides within 10 minutes.

Necessary for microencapsulation of the three is carboxymethylcellulose, xanthan gum, Kappa-carrageenan were industrial production, widely used in the food industry.

EXAMPLE 1. Obtaining microcapsules of metribuzin in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of metribuzin dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of metribuzine independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,396 g of the microcapsules. The yield was 99%.

EXAMPLE 2. Obtaining microcapsules haloxyfop-p-methyl in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g haloxyfop-p-methyl is dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation of the education Galax is the FOP-p-methyl independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,392 g of the microcapsules. The yield was 98%.

EXAMPLE 3. Obtaining microcapsules of clethodim in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of clethodim dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of clethodim independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,352 g of the microcapsules. The yield was 88%.

EXAMPLE 4. Obtaining microcapsules of metolachlor in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug A with as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of metolachlor dissolved in 0.5 ml DMSO and transferred to the solution strikeback is metiltselljulozy in benzene. After the formation after the formation of metolachlor independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,360 g of the microcapsules. The yield was 90%.

EXAMPLE 5. Obtaining microcapsules of clopyralid in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug A with as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of clopyralid dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of clopyralid independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,360 g of the microcapsules. The yield was 90%.

EXAMPLE 6. Obtaining microcapsules KINTO Duo in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as a surfactant to the resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g KINTO Duo dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of KINTO Duo independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,320 g of the microcapsules. The yield was 88%.

EXAMPLE 7. Obtaining microcapsules of tributed methyl in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of tributed methyl dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of tribution methyl independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride. Received 0,368 g of the microcapsules. The yield was 92%.

EXAMPLE 8. Obtaining microcapsules of propiconazole and tebuconazole in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5%solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of propiconazole and tebuconazole dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of propiconazole and tebuconazole independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,340 g of the microcapsules. The yield was 90%.

EXAMPLE 9. Obtaining microcapsules fenoxaprop-p-ethyl in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g fenoxaprop-p-ethyl is dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of fenoxaprop-p-ethyl independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride. Received 0,368 g of the microcapsules. The yield was 92%.

EXAMPLE 10. Obtaining microcapsules dioctylphthalate in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of dioctylphthalate was dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of the dioctylphthalate independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0.375 g of microcapsules. The yield was 94%.

EXAMPLE 11. Obtaining microcapsules sorbitol in Kappa-carragenan, the ratio of 1:3

To 6 g of 5% solution of Kappa-carrageenan in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of sorbitol dissolved in 0.5 ml DMSO and transferred to a solution of Kappa-carrageenan in benzene. After the formation after the formation of sorbitol independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is sucked fil is re SCHOTT 16 class long washed with acetone, dried in a desiccator over calcium chloride.

Received 0,325 g of the microcapsules. The yield was 81%.

EXAMPLE 12. Obtaining microcapsules sorbitol in carragenan, the ratio of 1:3

To 6 g of 5% solution of carrageenan in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of sorbitol dissolved in 0.5 ml DMSO and transferred to the carrageenan solution in benzene. After the formation after the formation of sorbitol independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0.375 g of microcapsules. The yield was 94%.

EXAMPLE 13. Obtaining microcapsules kanamycin in Kappa-carragenan, the ratio of 1:3

To 6 g of 5% solution of Kappa-carrageenan in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of kanamycin dissolved in 0.5 ml DMSO and transferred to a solution of Kappa-carrageenan in benzene. After the formation after the formation of the kanamycin independent solid phase very slowly added dropwise 1 ml of distilled water. Polucheno.sostoyanie microcapsules are filtered on the filter SCHOTT 16 class long washed with acetone, dried in a desiccator over calcium chloride.

Received 0,345 g of the microcapsules. The yield was 86%.

EXAMPLE 14. Obtaining microcapsules of vitamin D in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of vitamin D dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of vitamin D is independent of the solid phase is very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,340 g of the microcapsules. The yield was 85%.

EXAMPLE 15. Obtaining microcapsules of the flavor of Mandarin in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of the flavor of Mandarin dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After about what adowanie after the formation of the flavor of tangerine independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,330 g of the microcapsules. The yield was 83%.

EXAMPLE 16. Obtaining microcapsules of the flavor of tomato in Kappa-carragenan, the ratio of 1:3

To 6 g of 5% solution of Kappa-carrageenan in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of kanamycin dissolved in 0.5 ml DMSO and transferred to a solution of Kappa-carrageenan in benzene. After the formation after the formation of the kanamycin independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,310 g of the microcapsules. The yield was 78%.

EXAMPLE 17. Obtaining microcapsules of the flavor of hazelnuts in Kappa-carragenan, the ratio of 1:3

To 6 g of 5% solution of Kappa-carrageenan in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of the flavor of hazelnut dissolved in 0.5 ml DMSO and transferred to a solution of Kappa-CT is Ajnana in benzene. After the formation after the formation of the flavor of hazelnut independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride. Received 0,345 g of the microcapsules. The yield was 86%.

EXAMPLE 18. Obtaining microcapsules kanamycin in the xanthan gum, the ratio of 1:3

To 6 g of 5% solution of xanthan gum in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of kanamycin dissolved in 0.5 ml DMSO and transferred to a solution of xanthan gum in benzene. After the formation after the formation of the kanamycin independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,235 g of the microcapsules. The yield was 59%.

EXAMPLE 19. Obtaining microcapsules of flavor coffee in Kappa-carragenan, the ratio of 1:3

To 6 g of 5% solution of Kappa-carrageenan in benzene added 0.01 g of the drug A with as surfactants. The resulting mixture was put on a magnetic stirrer and include the mixing. 0.1 g of the flavor of coffee dissolved in 0.5 ml DMSO and transferred to a solution of Kappa-carrageenan in benzene. After the formation after the formation of the flavor of coffee independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride. Received 0,340 g of the microcapsules. The yield was 85%.

EXAMPLE 20. Obtaining microcapsules coenzyme Q10the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of coenzyme Q10dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of coenzyme Q10independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,335 g of the microcapsules. The yield was 84%.

EXAMPLE 21. Obtaining microcapsules of sorbitol in the sodium carboxymethyl cellulose, sootnoshenie:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of sorbitol dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of sorbitol independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,330 g of the microcapsules. The yield was 83%.

EXAMPLE 22. Obtaining microcapsules mannitol Kappa-carragenan, the ratio of 1:3

To 6 g of 5% solution of Kappa-carrageenan in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of mannitol are dissolved in 0.5 ml DMSO and transferred to a solution of Kappa-carrageenan in benzene. After the formation after the formation of mannitol independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,345 g microcaps the L. The yield was 86%.

EXAMPLE 23. Obtaining microcapsules of the flavor of green Apple in Kappa-carragenan, the ratio of 1:3

To 6 g of 5% solution of Kappa-carrageenan in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of the flavor of green Apple dissolved in 0.5 ml DMSO and transferred to a solution of Kappa-carrageenan in benzene. After the formation after the formation of the flavor of green Apple independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0.375 g of microcapsules. The yield was 94%.

EXAMPLE 24. Obtaining microcapsules of the flavor of the paprika in Kappa-carragenan, the ratio of 1:1

To 6 g of 5% solution of Kappa-carrageenan in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of the flavor of the pepper dissolved in 0.5 ml DMSO and transferred to a solution of Kappa-carrageenan in benzene. After the formation after the formation of the flavor of paprika separate the solid phase is slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,430 g of the microcapsules. The yield was 72%.

EXAMPLE 25. Obtaining microcapsules of flavor cappuccino in Kappa-carragenan, the ratio of 1:1

To 6 g of 5% solution of Kappa-carrageenan in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of flavor cappuccino dissolved in 0.5 ml DMSO and transferred to a solution of Kappa-carrageenan in benzene. After the formation after the formation of the flavor cappuccino independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,430 g of the microcapsules. The yield was 72%.

EXAMPLE 26. Obtaining microcapsules of the flavor of Apple in Kappa-carragenan, the ratio of 1:1

To 6 g of 5% solution of Kappa-carrageenan in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of the flavor of the Apple of restore the t in 0.5 ml DMSO and transferred to a solution of Kappa-carrageenan in benzene. After the formation after the formation of the flavor of the Apple independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,420 g of the microcapsules. The yield was 70%.

EXAMPLE 27. Obtaining microcapsules of the flavor of green tea in Kappa-carragenan, the ratio of 1:1

To 6 g of 5% solution of Kappa-carrageenan in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of the flavor of green tea are dissolved in 0.5 ml DMSO and transferred to a solution of Kappa-carrageenan in benzene. After the formation after the formation of the flavor of green tea independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,425 g of the microcapsules. The yield was 71%.

EXAMPLE 28. Obtaining microcapsules of the flavor of whiskey in Kappa-carragenan, the ratio of 1:1

To 6 g of 5% solution of Kappa-carrageenan in benzene added 0.01 g pre is Arata Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of the flavor of whiskey dissolved in 0.5 ml DMSO and transferred to a solution of Kappa-carrageenan in benzene. After the formation after the formation of aromatase-torus with the smell of whiskey independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,500 g of the microcapsules. The yield was 83%.

EXAMPLE 29. Obtaining microcapsules kanamycin in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethylcellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of kanamycin dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of the kanamycin independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,320 g of the microcapsules. The yield was 80%.

EXAMPLE 30. Getting microca the Sul sorbitol in sodium alginate, the ratio of 1:3

To 6 g of 5% solution of sodium alginate in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of sorbitol dissolved in 0.5 ml DMSO and transferred into a solution of sodium alginate in benzene. After the formation after the formation of sorbitol independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,320 g of the microcapsules. The yield was 80%.

EXAMPLE 31. Obtaining microcapsules of fructose in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of fructose dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of fructose-independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride

Received 0,380 g of the microcapsules. The yield was 95%.

EXAMPLE 32. Obtaining microcapsules lactose in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug A with as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of lactose dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of lactose independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,350 g of the microcapsules. The yield was 88%.

EXAMPLE 33. Obtaining microcapsules mannitol in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of mannitol are dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of mannitol independent solid phase very slowly added dropwise 1 ml distillirovanna the water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,360 g of the microcapsules. The yield was 90%.

EXAMPLE 34. Obtaining microcapsules of fructose in the sodium alginate, the ratio of 1:1

To 6 g of 5% solution of sodium alginate in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of fructose dissolved in 0.5 ml DMSO and transferred into a solution of sodium alginate in benzene. After the formation after the formation of fructose-independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,450 g of the microcapsules. The yield was 75%.

EXAMPLE 35. Obtaining microcapsules lactose in the sodium alginate, the ratio of 1:3

To 6 g of 5% solution of sodium alginate in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of lactose dissolved in 0.5 ml DMSO and transferred into a solution of sodium alginate in benzene. After the formation after the formation of lactose independent t is erday phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules sucked PA filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,310 g of the microcapsules. The yield was 78%.

EXAMPLE 36. Obtaining microcapsules mannitol, sodium alginate, a ratio of 1:3

To 6 g of 5% solution of sodium alginate in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of mannitol are dissolved in 0.5 ml DMSO and transferred into a solution of sodium alginate in benzene. After the formation after the formation of mannitol independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,350 g of the microcapsules. The yield was 88%.

EXAMPLE 37. Obtaining microcapsules kanamycin in the sodium alginate, the ratio of 1:3

To 6 g of 5% solution of sodium alginate in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of kanamycin dissolved in 0.5 ml DMSO and transferred into a solution of sodium alginate in benzene. After the formation after the formation of the kanamycin independently is Oh solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,320 g of the microcapsules. The yield was 80%.

EXAMPLE 38. Obtaining microcapsules ampicilina in Kappa-carragenan, the ratio of 1:1

To 6 g of 5% solution of Kappa-carrageenan in benzene added 0.01 g of the drug A with as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g ampicilina dissolved in 0.5 ml DMSO and transferred to a solution of Kappa-carrageenan in benzene. After the formation after the formation of ampicillin independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,340 g of the microcapsules. The yield was 85%.

EXAMPLE 39. Obtaining microcapsules of streptocide in Kappa-carragenan, the ratio of 1:1

To 6 g of 5% solution of Kappa-carrageenan in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of streptocide dissolved in 0.5 ml DMSO and transferred to a solution of Kappa-carrageenan in benzene. After the formation after the formation of the p is Procida independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,335 g of the microcapsules. The yield was 84%.

EXAMPLE 40. Obtaining microcapsules benzylpenicillin in Kappa-carragenan, the ratio of 1:1

To 6 g of 5% solution of Kappa-carrageenan in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g benzylpenicillin dissolved in 0.5 ml DMSO and transferred to a solution of Kappa-carrageenan in benzene. After the formation after the formation of benzilpenitsillinom independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,345 g of the microcapsules. The yield was 86%.

EXAMPLE 41. Obtaining microcapsules of streptocide in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surface-active substances.

The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of streptocide dissolved in 0.5 ml DMSO and transferred to the solution nutricosmetic is llulose in benzene. After the formation after the formation of the streptocide independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,325 g of the microcapsules. The yield was 81%.

EXAMPLE 42. Obtaining microcapsules ampicilina in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g ampicilina dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of ampicillin independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride. Received 0,330 g of the microcapsules. The yield was 83%.

EXAMPLE 43. Obtaining microcapsules benzylpenicillin in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surface-active substances the. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g benzylpenicillin dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of benzilpenitsillinom independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,320 g of the microcapsules. The yield was 80%.

EXAMPLE 44. Obtaining microcapsules of streptomycin in the sodium carboxymethyl cellulose, the ratio of 1:3

To 6 g of 5% solution of sodium carboxymethyl cellulose in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g streptomycin dissolved in 0.5 ml DMSO and transferred into a solution of sodium carboxymethyl cellulose in benzene. After the formation after the formation of streptomycin independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,340 g of the microcapsules. The yield was 85%.

EXAMPLE 45. Getting microcaps is the streptocide in sodium alginate, the ratio of 1:3

To 6 g of 5% solution of sodium alginate in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g of streptocide dissolved in 0.5 ml DMSO and transferred into a solution of sodium alginate in benzene. After the formation after the formation of the streptocide independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,320 g of the microcapsules. The yield was 80%.

EXAMPLE 46. Obtaining microcapsules of streptomycin in the sodium alginate, the ratio of 1:3

To 6 g of 5% solution of sodium alginate in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g streptomycin dissolved in 0.5 ml DMSO and transferred into a solution of sodium alginate in benzene. After the formation after the formation of streptomycin independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received of 0.30 g of the microcapsules. The yield was 83%.

EXAMPLE 47. Obtaining microcapsules ampicilina in the sodium alginate, the ratio of 1:3

To 6 g of 5% solution of sodium alginate in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g ampicilina dissolved in 0.5 ml DMSO and transferred into a solution of sodium alginate in benzene. After the formation after the formation of ampicilina independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT 16 class then washed with acetone, dried in a desiccator over calcium chloride.

Received 0,345 g of the microcapsules. The yield was 86%.

EXAMPLE 48. Obtaining microcapsules benzylpenicillin in the sodium alginate, the ratio of 1:3

To 6 g of 5% solution of sodium alginate in benzene added 0.01 g of the drug Is as surfactants. The resulting mixture was put on a magnetic stirrer and include mixing. 0.1 g benzylpenicillin dissolved in 0.5 ml DMSO and transferred into a solution of sodium alginate in benzene. After the formation after the formation of benzilpenitsillinom independent solid phase very slowly added dropwise 1 ml of distilled water. The resulting suspension of microcapsules is filtered by the filter SCHOTT is 16 class long washed with acetone, dried in a desiccator over calcium chloride.

Received 0,350 g of the microcapsules. The yield was 88%.

The obtained microcapsules drugs, polysaccharides, herbicides, fragrances, vitamins. In the above examples was used shell, suitable for use in the food industry. Most of the drugs, microcapsulation are given in the examples are liquids. Microencapsulation of liquids is a challenging task, as it is necessary to find the conditions for the formation of microcapsules of liquid substances. In this case, this problem is solved.

The proposed method is suitable for pharmaceutical, agricultural, food industry due to the minimal loss of speed, ease of acquisition and allocation of microcapsules with high yield. Thus, it is universal.

The method of producing microcapsules, characterized in that the obtaining microcapsules is carried out by physical and chemical deposition method by nerastvorim using benzene as a precipitator.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to microcapsulation of drug preparations of cephalosporins referred to β-lactam antibiotics in konjac gum by physical-chemical precipitation in a non-solvent. Konjac gum is used as a microcapsule membrane. The microcapsules are prepared by physical-chemical precipitation in the non-solvent with using two precipitation agents - carbinol and chloroform. The process of microcapsules is carried out at 25°C with no special equipment required.

EFFECT: method according to the invention provides simplifying and accelerating the process of microcapsules of drug preparations of cephalosporins, and reducing losses (higher weight yield).

4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to microencapsulation, particularly microencapsulation of pesticides. The method consists in physical-chemical precipitation using two precipitants - butanol and ethanol. The microcapsule cladding is sodium carboxymethyl cellulose.

EFFECT: invention increases mass output of microcapsules while simplifying the process of producing microcapsules.

7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to microencapsulation of drugs through the example of rivanol which can be used as an antimicrobial, antifungal topical preparation. A method for preparing microcaplues of rivanol in a water-soluble polymer representing polyvinyl alcohol or polyvinyl pyrrolidone is implemented by physical-chemical precipitation with a solvent wherein a precipitant is acetone. The process is carried out at 25°C with no special equipment required.

EFFECT: method for preparing the microcapsules of rivanol provides simplifying the process of microencapsulation.

13 dwg, 5 ex

FIELD: nanotechnology.

SUBSTANCE: device (50) for preparation of nanoparticles on a continuous basis comprises the first feeding device (1a) with the first feeding load (9) connected to the source (7) of the starting material, the first reactor (2) comprising the first heated reaction zone (13), the second reactor (3) comprising the second heated reaction zone (15), where all the said devices are connected to the channel of the material flow successively in the said order, at least one pressure control unit (18) mounted in the said channel of the material flow, a mixer (5) mounted in the said channel of the material flow between the first reactor (2) and the second reactor (3), the second feeding device (lb) with the second feeding pump (10) connected to the source (8) of the starting material, and the second feeding pump (10) is in liquid junction with the mixer (5), the control device (22) made with the ability to control the pressure value setting with the said pressure control unit (18) and/or the temperature value of the said heated reaction zones (13 and 15). The device is characterised in that after each heated reaction zone (13) in the channel of the material flow the appropriate cooling device (14, 16) is mounted for reducing the size of the nanoparticles in the process of their preparation, and the cooling devices (14, 16) are additionally made with the ability to cease this process of nanoparticles preparation. Also the invention relates to use of the device for preparation of nanoparticles/nanoemulsions/colloidal solutions.

EFFECT: invention enables to obtain nanoparticles which properties can be modified in the course of this process.

8 cl, 10 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical microcapsulation of cephalosporins related to β-lactam antibiotics. As a microcapsule shell, the method of pharmaceutical microcapsulation of cephalosporins uses konjac gum; the microcapsules are prepared by physical-chemical technology implying the precipitation in a non-solvent using two precipitants - carbinol and diethyl ester in ratio 1:3; the method is conducted at 25°C with no special equipment.

EFFECT: invention provides simplified and accelerated preparation of the water-soluble pharmaceutical microcapsules of cephalosporins in konjac gum, loss reduction in preparing the microcapsules (higher yield-mass).

3 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to medicine and describes method of obtaining delivering particles of fragrance, containing core material and envelope, said envelope at least partially surrounds said core material and at least 75% of said delivering particles of fragrance are characterised by tensile strength from approximately 0.2 MPa to approximately 10 MPa, with particle size from approximately 1 micron to approximately 80 micron and thickness of particle walls from approximately 60 nm to approximately 250 nm; and said delivering particles of fragrance are characterised by release of fragrance from 0% to approximately 30%. In addition to creation of possibility to reduce number of agent which produces favourable impact, such particles make it possible to extend spectrum of applied agents which produce favourable impact.

EFFECT: in cases of application in compositions, for instance, detergents, or compositions for fabric care, such particles increase efficiency of delivery of agent which produces favourable impact, making it possible to use reduced amounts of agents which produce favourable impact.

11 cl, 9 tbl, 13 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a powder coating composition obtained from aqueous dispersion containing polymer-encapsulated particles, said particles including particles encapsulated in a brittle polymer which can easily break up under ambient conditions. The invention also discloses a method of preparing an aqueous dispersion of particles encapsulated in a brittle polymer, a base which is at least partially coated with a coating deposited from said composition, a multilayer composite coating, a method of preparing a powder coating composition, a method of preparing an aqueous dispersion of particles encapsulated in a brittle polymer and a powder coating composition formed from said dispersion prepared using said method, as well as a reflecting surface which is at least partially coated with a layer which gives the colour of an uncovered coating deposited from disclosed powder coating compositions.

EFFECT: obtaining aqueous dispersion of particles encapsulated in a brittle polymer in which repeated agglomeration of particles is minimised and which enables to obtain a powder coating composition which contains multiple polymer-encapsulated particles having maximum turbidity so that the coating has absorption or reflection in the visible spectrum which is close to that of the given coating.

22 cl, 14 ex, 1 tbl

FIELD: process engineering.

SUBSTANCE: invention relates to production of minor spherical particles of active agent in sole liquid phase solution. Sole liquid phase comprises active agent, agent facilitating phase separation and first thinner. Phase separation is induced at controller rate in solution to cause separation active agent into "fluid-solid" and to form liquid and solid phases. Note here that inducing comprises solution cooling. Solid phase contains minor spherical particles of active agent. Liquid phase comprises agent facilitating phase separation and thinner. Minor spherical particles feature particle size varying from 0.01 mcm to about 200 mcm.

EFFECT: minor spherical particles of active agent in sole liquid phase solution.

77 cl, 49 dwg, 4 tbl, 36 ex

FIELD: process engineering.

SUBSTANCE: invention maybe used for efficient fire extinguishing, fast cooling of overheated structures and production of lower-flammability compounds. Microcapsules have a micro-sphere-like core containing water or water solution in gel state, main shell around said core to provide for core stable shape and composition and rule out water evaporation therefrom the core, and, additionally, comprises outer shell with lyophilic properties. Versions of proposed methods comprises producing aforesaid core via interaction of appropriate initial water solutions to be placed in microsphere and containing appropriate components of the shell with components of solutions to be precipitated and used for producing and cross-linking of gel, and producing additional lyophilic shell via interaction of components of initial solutions with appropriate components in organic medium.

EFFECT: high efficiency in fire extinguishing or fast cooling of overheated structures.

21 cl, 1 tbl, 10 ex

FIELD: chemistry.

SUBSTANCE: invention relates to use of polymer material, and specificaly to use of particulate polymer material as an active agent carrier. The polymer material is a polymer obtained from copolymerisation of pyrrole with quadratic or croconic acid or its derivative.

EFFECT: use in accordance with the invention enables to use polymer material as a composition in form of particles as an absorbent or prolonged release agent.

16 cl, 8 dwg, 1 tbl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to microcapsulation of drug preparations of cephalosporins referred to β-lactam antibiotics in konjac gum by physical-chemical precipitation in a non-solvent. Konjac gum is used as a microcapsule membrane. The microcapsules are prepared by physical-chemical precipitation in the non-solvent with using two precipitation agents - carbinol and chloroform. The process of microcapsules is carried out at 25°C with no special equipment required.

EFFECT: method according to the invention provides simplifying and accelerating the process of microcapsules of drug preparations of cephalosporins, and reducing losses (higher weight yield).

4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to microencapsulation of drugs through the example of rivanol which can be used as an antimicrobial, antifungal topical preparation. A method for preparing microcaplues of rivanol in a water-soluble polymer representing polyvinyl alcohol or polyvinyl pyrrolidone is implemented by physical-chemical precipitation with a solvent wherein a precipitant is acetone. The process is carried out at 25°C with no special equipment required.

EFFECT: method for preparing the microcapsules of rivanol provides simplifying the process of microencapsulation.

13 dwg, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical microcapsulation of cephalosporins related to β-lactam antibiotics. As a microcapsule shell, the method of pharmaceutical microcapsulation of cephalosporins uses konjac gum; the microcapsules are prepared by physical-chemical technology implying the precipitation in a non-solvent using two precipitants - carbinol and diethyl ester in ratio 1:3; the method is conducted at 25°C with no special equipment.

EFFECT: invention provides simplified and accelerated preparation of the water-soluble pharmaceutical microcapsules of cephalosporins in konjac gum, loss reduction in preparing the microcapsules (higher yield-mass).

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: declared group of inventions refers to a pharmacological composition for intranasal introduction for cerebral delivery, and a method for preparing said composition. The declared composition comprises a container base formed by porous particles of calcium carbonate and titanium dioxide of particle size 100-5000 nm and a pharmacologically active component - loperamide. The container surface is modified by surfactants specified in polysorbates, or by polymers specified in a group containing glycosaminoglycanes and polypeptides, or their combination. A method for preparing the pharmacological composition consists in preparing the container base by porous particle synthesis, sorption of loperamide in its pore spaces and modification of the container surface by polymers and surfactants by container incubation in their solutions.

EFFECT: invention provides preparing the pharmacological composition which is applicable for cerebral loperamide delivery after the intranasal introduction.

5 cl, 5 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to composition for peroral introduction, which possesses properties of modified release. According to invention composition includes pharmaceutically acceptable excipients and complex medication-ion-exchanging resin with coating with modified release, which contains pharmaceutically active medication, combined with pharmaceutically acceptable ion-exchanging resin. Complex has solidified barrier coating with high rupture strength, water-permeable, water-insoluble, which contains polyvinyl acetate polymer, stabiliser and efficient amount of plastifier. Said coating is in fact non-sticky, when applied onto complex in absence of anti-adhesive preparation, if composition presents tablet, complex medication-ion-exchanging resin with coating additionally contains release-retarding substance in matrix together with complex medication-ion-exchanging resin. Invention also relates to product with modified release, including package which contains composition described above.

EFFECT: invention ensures regulated prolonged active agent release without breaking coating integrity, without application of water-soluble impregnating substances and without agglomeration of complex particles during application of coating.

27 cl, 22 ex

FIELD: medicine.

SUBSTANCE: there are described oral dosage forms of risedronate containing safe and effective amount of a pharmaceutical composition containing risedronate, a chelating agent and an agent for effective delayed release of risedronate and the chelating agent in small intestine. The pharmaceutical composition is directly released in a small intestine of a mammal with ensuring pharmaceutically effective absorption of bisphosphonate together with or without food or drinks. Present invention essentially reduces interaction between risedronate and food or drinks which leads to that the active component of bisphosphonate becomes inaccessible to absorption. Thus, the final oral dosage form can be taken with and without food. Further, present invention covers delivery of risedronate and the chelating agent in a small intestine, essentially reducing irritation of upper gastrointestinal tract associated with bisphosphonate therapy. These advantages simplify previous, complicated regimens and can lead to more complete observance of the bisphosphonate therapy regimen.

EFFECT: present invention essentially reduces interaction between risedronate and food or drinks which leads to that the active component of bisphosphonate becomes inaccessible to absorption.

23 cl, 12 ex

FIELD: medicine.

SUBSTANCE: invention refers to a carrier for drugs, biologically active substances, biological objects used in medicine for diagnostics and treatment in pharmaceutical industry. The carrier represents a material sensitive to external magnetic or electric fields and consisting of magnetic or ferroelectric material filmed with biocompatible thermosensitive, biodegradable polymer and/or dispersed in thermosensitive medium properties of which change with varying temperature relative to that of human body within 15.9 to 42°C. The magnetic or ferroelectric materials are made of substance with great magnetocaloric or electrocaloric component effect 1 to 13 K, have temperature of magnetic or ferroelectric phase transition within temperature range 33 to 37°C, and are chosen from the group including rare-earth, transition and precious metals, their alloys and compounds.

EFFECT: invention also concerns methods of controlled drug delivery by means of such carrier with enabling release thereof (regulated desorption) in the preset point.

32 cl, 9 ex

FIELD: medicine; pharmacology.

SUBSTANCE: minitablets have a kernel and an external cover which makes 2-15% of gross weight of minitablets, the kernel of the specified minitablets, includes a venlafaxine hydrochloride, microcrystallic cellulose and a polyvinylpyrolidone, and the specified cover includes polymer, insoluble in water, and a polymer, soluble in water.

EFFECT: provision of levels of concentration in a blood plasma above the minimum therapeutic concentration during the long period of time.

10 cl, 1 dwg, 1 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention discovers improved composition for profile control of active compound release through the digestive tract, including particles, especially granules, containing the active compounds. They are covered with coating material, solution of which depends on pH value, or polymethacrylate material, solution of which, for preference, depends on pH value, the definite thickness, desirable place and speed of the active compound release. In preferable compositions two or more particles, in which particles of each multitude are covered with the coating material, the solution which depends on pH value, or polymethacrylate material, of different thickness in comparison with the particles of each other multitude, are contained in capsules with enterosoluble coating and provide the active substance release in different desirable places of the digestive tract.

EFFECT: provision of active substance release in desirable places of digestive tract.

28 cl, 7 dwg, 9 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to sustained-release medicinal formulation composition comprising venlafaxin hydrochloride as an active component. In this formulation venlafaxin hydrochloride in common with a binding agent is applied on inert core as lozenge form (nonpareil) followed applying with a cover-insulating polymeric layer for providing stability and additional cover with external polymeric layer providing the sustained-release of venlafaxin hydrochloride.

EFFECT: improved and valuable properties of composition.

18 cl, 1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and may be used for treating septic wounds and burns. A composition possessing antibacterial action contains active metal biocomplexes with 5-nitroimidazole and β-pyridine carboxylic acid and a base providing a soft dosage form. As a gelling agent, there may be used modified cellulose derivatives, additionally comprising methyl monosilane hydrogel (enterosgel) and/or polyvinylpyrrolidone, or an alloy of polyethylene oxide-400 and polyethylene oxide-1500. As a mixture of hydrophilic substances, the base contains substances specified in a group of: polyethylene oxides, dimexide, glycerol and aerosol, may comprise at least one target additive of: anaesthetic - trimecaine, pyrromecaine, lidocaine, or a mixture thereof, a repair process stimulator - methyluracil, acemine, solcoseryl, Spirulina microalgae (Spirulina platensis), or a mixture thereof, antiseptic - miramistine, chlorhexidine digluconate, dioxidine or a mixture thereof. The composition is presented in the form of an ointment or gel.

EFFECT: invention provides the improved microcirculation in wound tissues, as well as anti-inflammatory action, repair process stimulation.

5 cl, 6 tbl, 4 ex

Up!